Perrigo Co. partner Cobrek Pharmaceuticals Inc. has received final approval from the Food and Drug Administration for betamethasone valerate foam (0.12%), a psoriasis medication.


Perrigo, Cobrek Pharmaceuticals, betamethasone valerate foam, Luxiq Foam, generic version, Luxiq Foam generic, Stiefel, scalp psoriasis, psoriasis medication






























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Perrigo set to roll out Luxiq Foam generic

November 28th, 2012

ALLEGAN, Mich. – Perrigo Co. partner Cobrek Pharmaceuticals Inc. has received final approval from the Food and Drug Administration for betamethasone valerate foam (0.12%), a psoriasis medication.

Perrigo said Tuesday that it has manufactured the product, a generic version of Stiefel's Luxiq Foam, and is set to begin commercial shipments on Jan. 15, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.

Betamethasone valerate foam 0.12% is indicated for the relief of scalp psoriasis. Brand annual sales were approximately $40 million.

"This is our sixth product approval using a foam dosage form, which requires specialized development and manufacturing capabilities," stated Perrigo chairman and chief executive officer Joseph Papa. "It is an example of the excellent partnership we have with Cobrek, and we are committed to making quality health care more affordable for our customers."

More Supplier News Breaks >>
Advertisement